

CITATION REPORT

List of articles citing

The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort

DOI: 10.1111/j.1365-2036.2006.02974.x

Alimentary Pharmacology and Therapeutics, 2006, 24, 319-30

Source: <https://exaly.com/paper-pdf/40425920/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
180	Are we ready for top-down therapy for inflammatory bowel diseases: con. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007 , 1, 249-55	4.2	1
179	Medical management of Crohn's disease. 2007 , 20, 269-81		9
178	[Common errors in the management of the seriously ill patient with inflammatory bowel disease]. 2007 , 30, 294-314		0
177	[Current status of inflammatory bowel disease treatment]. 2007 , 207, 298-300		0
176	Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. 2007 , 132, 507-15		201
175	Review article: appropriate use of corticosteroids in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 313-29	6.1	56
174	Ulcerative colitis. 2007 , 35, 277-282		5
173	Acute and chronic megacolon. 2007 , 10, 237-47		13
172	Association of SLC22A4/5 polymorphisms with steroid responsiveness of inflammatory bowel disease in Japan. 2008 , 51, 598-603		9
171	Azatioprina en el tratamiento de la colitis ulcerosa. 2008 , 7, 31-32		
170	European evidence-based Consensus on the management of ulcerative colitis: Current management. <i>Journal of Crohn's and Colitis</i> , 2008 , 2, 24-62	1.5	371
169	Therapeutic options in acute severe ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008 , 2, 357-70	4.2	12
168	Bowel ultrasound and mucosal healing in ulcerative colitis. <i>Digestive Diseases</i> , 2009 , 27, 285-90	3.2	39
167	Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 375-82	4.5	118
166	Positioning biologic agents in the treatment of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1570-82	4.5	12
165	Immunomodulation does not alter histology in resected Crohn's disease. <i>Techniques in Coloproctology</i> , 2009 , 13, 295-300	2.9	4
164	Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 29, 843-54	6.1	17

163	Treatment of steroid-naïve ulcerative colitis. 2009 , 10, 1449-60		5
162	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. <i>Gastroenterology Clinics of North America</i> , 2009 , 38, 577-94	4.4	19
161	Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. 2009 , 19, 77-85		28
160	Ulcerative colitis: current medical therapy and strategies for improving medication adherence. 2009 , 21, 1-8		15
159	Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 2002-7	4	24
158	Ulcerative colitis in a Southern European country: a national perspective. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 822-9	4.5	10
157	Ulcerative colitis in Madrid, Spain: current management. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1826-7	4.5	1
156	Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 1036-41	6.1	38
155	Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1297-306	6.1	37
154	What determines the later clinical course of patients who do not undergo colectomy at the first attack? A Japanese cohort study on ulcerative colitis. <i>Digestion</i> , 2010 , 81, 104-12	3.6	14
153	[Treatment of Crohn's disease: step-up or top-down?]. 2010 , 135, 1694-8		0
152	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. 2010 , 94, 1-18		26
151	Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 269-74	1.5	24
150	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 28-62	1.5	1071
149	Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1150-7	0.7	80
148	Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. 2011 , 9, 483-489.e3		199
147	The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a review. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 81-90	1.5	6
146	Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 196-202	1.5	21

145	Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 301-16	1.5	30
144	Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 397-401	1.5	21
143	Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 644-59, quiz 660	0.7	437
142	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. <i>American Journal of Gastroenterology</i> , 2011 , 106, 199-212, quiz 213	0.7	291
141	Variation in the glucocorticoid receptor gene (NR3C1) may be associated with corticosteroid dependency and resistance in children with Crohn's disease. 2011 , 21, 454-60		29
140	Systematic review: the role of tacrolimus in the management of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1282-94	6.1	48
139	Ulcerative colitis. 2011 , 39, 224-228		2
138	Immediate and long-term outcomes of corticosteroid therapy in pediatric Crohn's disease patients. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 954-62	4.5	12
137	Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators--a population-based study. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1731-40	4.5	27
136	Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 2308-17	4.5	16
135	Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 2497-502	4.5	23
134	[Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. <i>Zeitschrift Fur Gastroenterologie</i> , 2011 , 49, 1276-341	1.6	127
133	5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 413-20	0.7	82
132	Ulcerative colitis: Paediatric ulcerative colitis--can we predict proctocolectomy?. 2012 , 9, 494-5		2
131	Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?. <i>Digestive Diseases</i> , 2012 , 30, 368-75	3.2	52
130	Editorial (Hot Topic :Randomized Clinical Trials in Inflammatory Bowel Disease). 2012 , 7, 255-255		
129	Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn's Disease. 2012 , 7, 307-313		1
128	Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 744-54 ^{6.1}		14

127	Immunotherapy in inflammatory bowel disease. 2012 , 96, 525-44, x		27
126	[Apheresis in inflammatory bowel disease. A valid option?]. 2012 , 35, 22-31		3
125	[Systemic amyloidosis in inflammatory bowel disease]. 2012 , 35, 259-65		3
124	Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. <i>Digestive and Liver Disease</i> , 2012 , 44, 206-10	3.3	36
123	Guidelines for the management of Crohn's disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. 2012 , 6, 317-338		5
122	Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. 2012 , 47, 359-65		21
121	Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. 2012 , 181, 65-71		6
120	[Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. 2013 , 36, 127-46		22
119	Efficacy, safety and tolerability of vedolizumab in patients with inflammatory bowel disease: the ENTRANCE study. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, 636-43	1.5	45
118	Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 129-36	6.1	53
117	Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 2963-9	4	25
116	Nanomedicines for the treatment of inflammatory bowel diseases. 2013 , 5,		5
115	An evolutionary perspective on the causes and treatment of inflammatory bowel disease. 2013 , 29, 350-6		2
114	Medical management of Crohn's disease. 2013 , 104-122		
113	MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7947-54	5.6	25
112	[Differences in the prognosis according to the periods of diagnosis in ulcerative colitis]. 2014 , 64, 93-7		1
111	Early predictors of responses and clinical outcomes of corticosteroid treatment for severe ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2014 , 49, 424-33	2.4	5
110	Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 949-62	4.2	9

109	[Azathioprine in Crohn's disease therapy--guidance against the background of recent studies]. <i>Zeitschrift Fur Gastroenterologie</i> , 2014 , 52, 1423-30	1.6	5
108	The role of integrin antagonists in the treatment of inflammatory bowel disease. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1815-23	5.4	4
107	Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease - a nationwide study of 1035 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 374-81	6.1	32
106	Peroxisome proliferator-activated receptor gamma in the colon: inflammation and innate antimicrobial immunity. 2014 , 48 Suppl 1, S23-7		17
105	Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1375-81	4.5	19
104	An overview of the natural history of inflammatory bowel diseases. <i>Digestive Diseases</i> , 2014 , 32, 320-7	3.2	31
103	Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers. 2014 , 34, 37-42		3
102	Steroid use in Crohn's disease. 2014 , 74, 313-24		7
101	Therapeutic peptides in inflammatory bowel disease. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 455-66	5.6	0
100	Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1159-70	4	11
99	PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. 2014 , 93, e326		52
98	Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1348-58	4.5	9
97	Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study. 2015 , 27, 1270-5		5
96	Optimal management of steroid-dependent ulcerative colitis. 2015 , 8, 293-302		12
95	Systemic Corticosteroids for Inflammatory Disorders in Pediatrics. 2015 ,		
94	Glucocorticoids in Pediatric Gastrointestinal Disorders. 2015 , 105-121		
93	Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 156-63	1.5	57
92	Ulcerative colitis. 2015 , 43, 276-281		5

91	Perioperative corticosteroid management for patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 221-8	4.5	9
90	Crohn's Disease. 2015 ,		1
89	Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. 2016 , 7, 5-20		34
88	A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. 2016 , 2016, 3162595		25
87	A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease. <i>Intestinal Research</i> , 2016 , 14, 248-57	4.1	5
86	Review article: the practical management of acute severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 482-513	6.1	55
85	Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 117-26	6.1	42
84	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 360-70	3.3	29
83	Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1635-40	4	7
82	Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. <i>Scandinavian Journal of Gastroenterology</i> , 2016 , 51, 700-5	2.4	12
81	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017 , 49, 604-617	3.3	34
80	Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1025-1034	4	8
79	Medical Treatment of Inflammatory Bowel Disease. 2017 , 229-239		
78	Coloproctology. 2017 ,		6
77	Granulocitopenia en 2017. Puesta al día. <i>Enfermedad Inflamatoria Intestinal Al Día</i> , 2017 , 16, 62-69		
76	A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 991-997	4.5	7
75	French national consensus clinical guidelines for the management of Crohn's disease. <i>Digestive and Liver Disease</i> , 2017 , 49, 368-377	3.3	13
74	The biologics of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 175-184	5.4	6

73	Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice. <i>Digestion</i> , 2017 , 96, 119-126	3.6	9
72	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 3-25	1.5	1087
71	Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era". <i>Gastroenterology Report</i> , 2017 , 5, 165-177	3.3	22
70	Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. <i>World Journal of Gastroenterology</i> , 2017 , 23, 6628-6638	5.6	63
69	A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 437-444	4.1	4
68	Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDL Cohort. <i>American Journal of Gastroenterology</i> , 2018 , 113, 384-395	0.7	8
67	The Natural History of Newly Diagnosed Ulcerative Colitis in Patients with Concomitant Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2062-2067	4.5	10
66	Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy. <i>Techniques in Coloproctology</i> , 2018 , 22, 941-946	2.9	6
65	[Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) - AWMF Registry 021/009]. <i>Zeitschrift Fur Gastroenterologie</i> , 2018 , 56, 1087-1169	1.6	35
64	Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2740-2746	4	8
63	Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 883-897	4.2	13
62	Outcomes and prediction of corticosteroid therapy after successive courses of ulcerative colitis treatments. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 733-741	4.2	4
61	Current Concepts of Pharmacotherapy in Crohn's Disease. <i>Visceral Medicine</i> , 2019 , 35, 344-347	2.4	1
60	Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1138-1141	4	1
59	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , 2019 , 51, 613-620	3.3	8
58	A current overview of corticosteroid use in active ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 557-561	4.2	25
57	Do medications affect outcomes in pelvic pouch construction?. <i>Seminars in Colon and Rectal Surgery</i> , 2019 , 30, 2-6	0.3	
56	Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice. <i>Digestive Diseases</i> , 2019 , 37, 11-20	3.2	2

55 The Kock Pouch. **2019**,

54 Decoding the enigma of antiviral crisis: Does one target molecule regulate all?. *Cytokine*, **2019**, 115, 13-23 24

53 Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). *Zeitschrift Fur Gastroenterologie*, **2019**, 57, 162-241 1.6 25

52 ANP32E, a Protein Involved in Steroid-Refractoriness in Ulcerative Colitis, Identified by a Systems Biology Approach. *Journal of Crohn's and Colitis*, **2019**, 13, 351-361 1.5 18

51 The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials. *Nutrients*, **2020**, 12, 6.7 14

50 Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form). *Gastroenterology Clinics of North America*, **2020**, 49, 705-716 4.4 3

49 Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review. *Journal of Gastroenterology and Hepatology (Australia)*, **2021**, 36, 344-361 4 5

48 Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211036456 4.7 1

47 Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis. *JGH Open*, **2021**, 5, 377-381 1.8 1

46 Inflammatory Bowel Disease: A Personalized Approach. *Frontiers in Pediatrics*, **2020**, 8, 620545 3.4

45 Cytopheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. *World Journal of Gastroenterology*, **2021**, 27, 1194-1212 5.6 1

44 5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease. *Biomedicines*, **2021**, 9, 4.8 2

43 Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. *World Journal of Gastroenterology*, **2021**, 27, 3609-3629 5.6 13

42 Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis. *International Journal of Colorectal Disease*, **2021**, 36, 2081-2092 3 2

41 Corticosteroids. **2017**, 369-373 1

40 Aktualisierte S3-Leitlinie Colitis ulcerosa [Living Guideline. *Zeitschrift Fur Gastroenterologie*, **2020**, 58, e241-e326 1.6 6

39 Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids. *Digestive Diseases*, **2018**, 36, 33-39 3.2 3

38 Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. *F1000Research*, **2020**, 9, 3.6 38

37	CROHN'S DISEASE. CLINICAL RECOMMENDATIONS (PRELIMINARY VERSION). <i>Koloproktologia</i> , 2020 , 19, 8-38	0.8	34
36	Quality of care for patients with inflammatory bowel disease in East China. <i>World Journal of Gastroenterology</i> , 2008 , 14, 612-6	5.6	4
35	Current use of immunosuppressive agents in inflammatory bowel disease patients in East China. <i>World Journal of Gastroenterology</i> , 2009 , 15, 3055-9	5.6	12
34	Clinical epidemiology of ulcerative colitis in Arabs based on the Montr�l classification. <i>World Journal of Gastroenterology</i> , 2014 , 20, 17525-31	5.6	18
33	Albumin as a prognostic marker for ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 8008-8016	5.6	20
32	Healing Effects of Elaeagnus angustifolia Extract in Experimentally Induced Ulcerative Colitis in Rats. <i>Journal of Pharmacology and Toxicology</i> , 2014 , 10, 29-35	0.4	7
31	Predictors of Steroid Treatment Failure and Validation of Previous Models for Severe Attacks of Ulcerative Colitis. <i>Intestinal Research</i> , 2012 , 10, 251	4.1	1
30	Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. <i>Intestinal Research</i> , 2020 , 18, 355-378	4.1	7
29	Corticosteroids. 2013 , 325-329		
28	The Natural History of Ulcerative Colitis. 2014 , 23-30		
27	Optimal use of corticosteroids in gastroenterology and hepatology. <i>Journal of Translational Internal Medicine</i> , 2014 , 2, 53-58	3	2
26	Surgical Management of Crohn's Disease. 2015 , 143-161		
25	Chronisch-entz�ndliche Darmkrankheiten. 2015 , 36,		
24	Management of de Novo Crohn's Disease after Reconstructive Surgery with Continent Ileostomy in Ulcerative Colitis. 2019 , 143-165		
23	A Primer on IBD: Phenotypes, Diagnosis, Treatment, and Clinical Challenges. 2019 , 3-24		0
22	Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database. <i>Korean Journal of Clinical Pharmacy</i> , 2020 , 30, 102-112	0.2	
21	Corticosteroid Therapy. 2008 , 363-369		
20	Therapy of inflammatory bowel disease: step-up or top-down?. 183-191		

19	Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease. <i>Gastroenterology and Hepatology</i> , 2011 , 7, 295-301	0.7	2
18	The effect of calendula officinalis in therapy of acetic Acid induced ulcerative colitis in dog as an animal model. <i>Iranian Red Crescent Medical Journal</i> , 2011 , 13, 884-90	1.3	15
17	The Healing Effect of Teucrium polium in Acetic Acid-Induced Ulcerative Colitis in the Dog as an Animal Model. <i>Middle East Journal of Digestive Diseases</i> , 2012 , 4, 40-7	1.1	14
16	Inflammatory cells' role in acetic acid-induced colitis. <i>Advanced Biomedical Research</i> , 2014 , 3, 193	1.2	7
15	Current Therapy in Inflammatory Bowel Disease: Why and How We Need to Change?. <i>European Medical Journal Innovations</i> , 40-49	0	0
14	Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment.. <i>Scandinavian Journal of Gastroenterology</i> , 2022 , 1-10	2.4	1
13	Poor engagement and adherence predict neoplasia in inflammatory bowel disease: a case-control study.. <i>Internal Medicine Journal</i> , 2022 ,	1.6	
12	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.. <i>Gut</i> , 2021 ,	19.2	5
11	Analysis of the Therapeutic Effect of Changyanning on Intestinal Flora in Inflammatory Bowel Disease. <i>Contrast Media and Molecular Imaging</i> , 2022 , 2022, 1-8	3.2	1
10	Self-therapeutic metal-based nanoparticles for treating inflammatory diseases. <i>Acta Pharmaceutica Sinica B</i> , 2022 ,	15.5	1
9	Evolving Experimental Platforms to Evaluate Ulcerative Colitis. 2200018		
8	Risk Factors Affecting 90-day Readmission of Patients with Inflammatory Bowel Disease. 2022 , 14, 34-43		0
7	Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. 2022 , 28, 4959-4972		0
6	Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study. 2022 , 26, 1-118		0
5	Sexual Dysfunction in Female Patients with Inflammatory Bowel Disease: An Overview. Volume 15, 213-224		0
4	Effects of the Antioxidant Quercetin in an Experimental Model of Ulcerative Colitis in Mice. 2023 , 59, 87		0
3	3D printed infliximab suppositories for rectal biologic delivery. 2023 , 5, 100176		0
2	Identification and immunological characterization of cuproptosis-related molecular clusters in Ulcerative Colitis.		0

- 1 Mild Crohn's Disease: Definition and Management. **2023**, 25, 45-51

o